Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

doi:10.1111/imj.13311

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Internal medicine journal - 1 Jan 2017

Talaulikar Dipti, Tam Constantine S, Joshua Douglas, Ho Joy Phoebe, Szer Jeff, Quach Hang, Spencer Andrew, Harrison Simon, Mollee Peter, Roberts Andrew W, Horvath Noemi, Lee Cindy, Zannettino Andrew, Brown Ross, Augustson Bradley, Jaksic Wilfrid, Gibson John, Kalff Anna, Johnston Anna, Trotman Judith, Kalro Akash, Grigoriadis George, Ward Chris, Prince H Miles

Abstract excerpt

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Differentiation Factor 88

Share to Piperidines

Share to Plasma Cells

Share to Practice Guidelines as Topic

Share to Rituximab

Share to Societies, Medical

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed

Identifiers

PMID: 28076910
DOI: 10.1111/imj.13311

Genes

MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.PMID 28076910Read ↗

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Semantic proximity Read ↗

How we manage patients with Waldenström macroglobulinaemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenströms Macroglobulinemia- a single center real world retrospective analysisSemantic proximity Read ↗

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.Semantic proximity Read ↗

The Direction of Modern Therapies in Waldenström Macroglobulinaemia.Semantic proximity Read ↗

How I treat Waldenström macroglobulinemia.Semantic proximity Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

New developments in the diagnosis and characterization of Waldenström's macroglobulinemia.Semantic proximity Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

Role of plasma cells in Waldenström macroglobulinaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.